461 related articles for article (PubMed ID: 27401179)
1. Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.
Maas RP; Muller-Hansma AH; Esselink RA; Murk JL; Warnke C; Killestein J; Wattjes MP
J Neurol; 2016 Oct; 263(10):2004-21. PubMed ID: 27401179
[TBL] [Abstract][Full Text] [Related]
2. Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort.
Wijburg MT; Warnke C; Barkhof F; Uitdehaag BMJ; Killestein J; Wattjes MP
J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):44-46. PubMed ID: 30100552
[TBL] [Abstract][Full Text] [Related]
3. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
Clifford DB; De Luca A; Simpson DM; Arendt G; Giovannoni G; Nath A
Lancet Neurol; 2010 Apr; 9(4):438-46. PubMed ID: 20298967
[TBL] [Abstract][Full Text] [Related]
4. [A case of progressive multifocal leukoencephalopathy presenting white matter MRI lesions extending over the cerebral cortex and a marked decrease in cerebral blood flow on SPECT, and associated with HTLV-I infection].
Takase K; Ohyagi Y; Furuya H; Nagashima K; Taniwaki T; Kira J
Rinsho Shinkeigaku; 2005 Jun; 45(6):426-30. PubMed ID: 16022467
[TBL] [Abstract][Full Text] [Related]
5. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.
Villar LM; Costa-Frossard L; Masterman T; Fernandez O; Montalban X; Casanova B; Izquierdo G; Coret F; Tumani H; Saiz A; Arroyo R; Fink K; Leyva L; Espejo C; Simó-Castelló M; García-Sánchez MI; Lauda F; Llufriú S; Álvarez-Lafuente R; Olascoaga J; Prada A; Oterino A; de Andrés C; Tintoré M; Ramió-Torrentà L; Rodríguez-Martín E; Picón C; Comabella M; Quintana E; Agüera E; Díaz S; Fernandez-Bolaños R; García-Merino JA; Landete L; Menéndez-González M; Navarro L; Pérez D; Sánchez-López F; Serrano-Castro PJ; Tuñón A; Espiño M; Muriel A; Bar-Or A; Álvarez-Cermeño JC
Ann Neurol; 2015 Mar; 77(3):447-57. PubMed ID: 25581547
[TBL] [Abstract][Full Text] [Related]
6. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
7. Application of "Mentzer's PML case definition" to natalizumab-treated patients in the setting of strict MRI-based pharmacovigilance.
Wijburg MT; Warnke C; Killestein J; Wattjes MP
J Neurol; 2020 Sep; 267(9):2599-2602. PubMed ID: 32385682
[TBL] [Abstract][Full Text] [Related]
8. Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question.
De Mercanti SF; Gned D; Matta M; Iudicello M; Franchin E; Clerico M
J Investig Med High Impact Case Rep; 2020; 8():2324709620939802. PubMed ID: 32646245
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Richert ND; Uitdehaag BM; Barkhof F; Killestein J
Mult Scler; 2016 Aug; 22(9):1174-83. PubMed ID: 26564995
[TBL] [Abstract][Full Text] [Related]
10. [Progressive multifocal leukoencephalopathy].
Warnke C; Wattjes MP; Adams O; Hartung HP; Martin R; Weber T; Stangel M
Nervenarzt; 2016 Dec; 87(12):1300-1304. PubMed ID: 27730274
[TBL] [Abstract][Full Text] [Related]
11. A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JCV testing.
Mazda ME; Brosch JR; Wiens AL; Bonnin JM; Kamer AP; Mattson DH; Snook RJ
Int J Neurosci; 2013 May; 123(5):353-7. PubMed ID: 23252596
[TBL] [Abstract][Full Text] [Related]
12. Atypical MRI features at early onset natalizumab-associated progressive multifocal leukoencephalopathy: a case report.
Piola M; Di Palma F; Mascoli N; Binda S; Arnaboldi M; Rezzonico M
J Neurol Sci; 2014 May; 340(1-2):213-4. PubMed ID: 24642511
[TBL] [Abstract][Full Text] [Related]
13. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D
JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729
[TBL] [Abstract][Full Text] [Related]
14. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
[TBL] [Abstract][Full Text] [Related]
15. Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
Fine AJ; Sorbello A; Kortepeter C; Scarazzini L
Ann Neurol; 2014 Jan; 75(1):108-15. PubMed ID: 24242357
[TBL] [Abstract][Full Text] [Related]
16. The effect of plasma exchange on serum anti-JC virus antibodies.
Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
[TBL] [Abstract][Full Text] [Related]
17. Review of progressive multifocal leukoencephalopathy and natalizumab.
Aksamit AJ
Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
[TBL] [Abstract][Full Text] [Related]
18. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.
Dong-Si T; Gheuens S; Gangadharan A; Wenten M; Philip J; McIninch J; Datta S; Richert N; Bozic C; Bloomgren G; Richman S; Weber T; Clifford DB
J Neurovirol; 2015 Dec; 21(6):637-44. PubMed ID: 25771865
[TBL] [Abstract][Full Text] [Related]
19. [Progressive multifocal leukoencephalopathy (PML). Report of a case diagnosed by amplification of JC virus DNA from cerebrospinal fluid (CSF)].
Ito D; Yogo Y; Okita H; Tanaka K; Koto A
Rinsho Shinkeigaku; 1998 Jan; 38(1):46-50. PubMed ID: 9597910
[TBL] [Abstract][Full Text] [Related]
20. MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.
Wijburg MT; Witte BI; Vennegoor A; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Uitdehaag BM; Barkhof F; Killestein J; Wattjes MP
J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1138-45. PubMed ID: 27530808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
